Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
12(71%)
Results Posted
0%(0 trials)
Terminated
1(6%)

Phase Distribution

Ph phase_1
8
47%
Ph phase_2
3
18%
Ph early_phase_1
1
6%

Phase Distribution

9

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution12 total trials
Early Phase 1First-in-human
1(8.3%)
Phase 1Safety & dosage
8(66.7%)
Phase 2Efficacy & side effects
3(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

12

trials recruiting

Total Trials

17

all time

Status Distribution
Active(12)
Completed(2)
Terminated(2)
Other(1)

Detailed Status

Recruiting12
Completed2
Terminated1
Suspended1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
17
Active
12
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (8.3%)
Phase 18 (66.7%)
Phase 23 (25.0%)

Trials by Status

recruiting1271%
completed212%
terminated16%
suspended16%
withdrawn16%

Recent Activity

12 active trials
Showing 5 of 17
recruitingearly_phase_1

Pilot Study of (MR) Imaging With Pyruvate (13C) to Detect High Grade Prostate Cancer

NCT02526368
suspendedphase_1

Early Assessment of Ovarian Cancer Aggressiveness by Metabolic Imaging

NCT05866679
recruitingphase_2

Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

NCT05746208
recruiting

Metabolic Characteristics of Brain Tumors Using Hyperpolarized Carbon-13 Magnetic Resonance Spectroscopic Imaging (MRSI)

NCT03067467
recruitingphase_1

Study Using Hyperpolarized 13C-Pyruvate Magnetic Resonance Spectroscopic Imaging in Patients With Pancreatic Cysts Undergoing Surgical Resection

NCT05873699
View all 17 trials

Clinical Trials (17)

Showing 17 of 17 trials
NCT02526368Early Phase 1

Pilot Study of (MR) Imaging With Pyruvate (13C) to Detect High Grade Prostate Cancer

Recruiting
NCT05866679Phase 1

Early Assessment of Ovarian Cancer Aggressiveness by Metabolic Imaging

Suspended
NCT05746208Phase 2

Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

Recruiting
NCT03067467

Metabolic Characteristics of Brain Tumors Using Hyperpolarized Carbon-13 Magnetic Resonance Spectroscopic Imaging (MRSI)

Recruiting
NCT05873699Phase 1

Study Using Hyperpolarized 13C-Pyruvate Magnetic Resonance Spectroscopic Imaging in Patients With Pancreatic Cysts Undergoing Surgical Resection

Recruiting
NCT03324360Phase 1

Role of Hyperpolarized 13C-Pyruvate MR Spectroscopy in Patients With Intracranial Metastasis Treated With (SRS)

Recruiting
NCT06600906

Hyperpolarized 13C MRI to Predict Response in Pancreatic Cancer

Recruiting
NCT04772456Phase 1

Hyperpolarized 13C-pyruvate Metabolic MRI With Infiltrating Gliomas

Recruiting
NCT05697406Phase 1

HP Pyruvate MRI in Cancers

Recruiting
NCT04698564Phase 2

Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging

Recruiting
NCT06103201Phase 1

Hyperpolarized 13C-pyruvate Metabolic MRI With Traumatic Brain Injury

Recruiting
NCT03057002

UTSW HP [13-C] Pyruvate Injection in HCM

Completed
NCT05599048Phase 1

Hyperpolarized 13C MRI as a Biomarker in Advanced Solid Tumors

Recruiting
NCT04968210

Metabolic Remodeling in Pulmonary Arterial Hypertension (PAH)

Completed
NCT06645691Phase 2

Hyperpolarized MR Imaging with Carbon-13 Pyruvate in the Human Body

Recruiting
NCT03129776Phase 1

Hyperpolarized 13C MR Imaging of Lactate in Patients With Locally Advanced Cervical Cancer (LACC) Cervical Cancer

Terminated
NCT03759704

Metabolic Characteristics of Sarcoma In Vivo Using HP 13-C Magnetic Resonance Spectroscopic Imaging (MRSI)

Withdrawn

All 17 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
17